|
|
|
ONLINE FEATURES
Book Reviews
BW Video
Columnists
Interactive Gallery
Newsletters
Past Covers
Philanthropy
Podcasts
Special Reports
BLOGS
The Auto Beat
Byte of the Apple
Europe Insight
Eye on Asia
Getting In
Investing Insights
The New Entrepreneur
NEXT: Innovation Tools & Trends
On Media
Technology at Work
The Tech Beat
Traveler's Check
TECHNOLOGY
Product Reviews
Tech Stats
Hands On
AUTOS
Home Page
Auto Reviews
Car Care & Safety
INNOVATION
& DESIGN Home Page Architecture Brand Equity Auto Design Game Room SMALLBIZ Smart Answers Success Stories Today's Tip FINANCE Investing: Europe Annual Reports Bloomberg BW50 SCOREBOARDS Hot Growth Companies: 2008 Mutual Funds Info Tech 100 B-SCHOOLS Undergrad Programs Rankings & Profiles |  |
MARCH 28, 2005
Sweet Or Salty With Senomyx  When CitiGroup (C
) took biotech outfit Senomyx (SNMX
) public on June 21, 2004, at 6 a share, there was scant interest. By Aug. 12 it had slipped to 5.65. But investors should have paid more attention: The stock has since doubled, to 11.98. Senomyx has developed a taste-receptor technology that intensifies salty or sweet flavors. Since last September, Nestlé (NSRGY
), Coca-Cola (KO
), Campbell Soup (CPB
), and Kraft Foods (KFT
) have signed up to use Senomyx compounds. "The ability to reduce sugar, salt, or artificial flavoring without sacrificing taste is a huge opportunity in this health-conscious society," says Robin Manners West of New Mexico's State Investment Council, which has purchased shares. Each compound, she says, works on a different flavor, so foodmakers can calculate how much to cut back on sugar, salt, or monosodium glutamate. On Mar. 3 two of Senomyx' enhancers got approval from the Flavor & Extract Manufacturers Assn., typically endorsed by the Food & Drug Administration, which dubbed them "generally regarded safe." These are the only approvals Senomyx needs. It expects its first sales in the first half of 2006, notes Steve Cohen of investment outfit Kellner DiLeo Cohen, which owns shares. He figures Senomyx will start making money only in 2007, given Senomyx' marketing timetable. He expects the company to earn 77 cents a share in 2007 and $1.50 to $2 in 2008. His 12-month price target: 20.
Note: Unless otherwise noted, neither the sources cited in Inside Wall Street nor their firms hold positions in the stocks under discussion. Similarly, they have no investment banking or other financial relationships with them.  By Gene G. Marcial Get BusinessWeek directly on your desktop with our RSS feeds.  Add BusinessWeek news to your Web site with our headline feed. Click to buy an e-print or reprint of a BusinessWeek or BusinessWeek Online story or video. To subscribe online to BusinessWeek magazine, please click here. Learn more, go to the BusinessWeekOnline home page  | | |
 Copyright 2005, Bloomberg L.P.Terms of Use | Privacy Notice |
Printer-Friendly Version